Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chromosomal imbalances in clear cell ependymomas.

Christian H Rickert1, Andrey Korshunov, Werner Paulus

  • 1Department of Anatomical Pathology, Royal Children's Hospital Melbourne, Melbourne, Australia, and Institute of Neuropathology, University Hospital Münster, Münster, Germany. christian.rickert@rch.org.au

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|May 2, 2006
PubMed
Summary

Clear cell ependymoma genetic features are largely unknown. Loss of chromosome 9 is a key molecular hallmark distinguishing this rare tumor subtype from other ependymomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

EClinicalMedicine·2026
Same author

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Neuro-oncology·2026
Same author

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

The Lancet. Child & adolescent health·2026
Same author

Author Correction: Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Nature·2026
Same author

Author Correction: Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors.

Nature communications·2026
Same author

Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Nature·2026

Area of Science:

  • Neuro-oncology
  • Cancer Genetics
  • Molecular Pathology

Background:

  • Clear cell ependymoma is a rare and diagnostically challenging subtype.
  • Its genetic features remain largely uncharacterized.
  • Understanding genetic aberrations is crucial for diagnosis and treatment.

Purpose of the Study:

  • To investigate the chromosomal imbalances in clear cell ependymomas.
  • To identify potential molecular hallmarks of this ependymoma subtype.
  • To compare genetic features between WHO grade II and III clear cell ependymomas.

Main Methods:

  • Comparative genomic hybridization (CGH) was performed on 13 clear cell ependymoma samples.
  • Analysis included five WHO grade II and eight WHO grade III cases.

Related Experiment Videos

  • Chromosomal aberrations were identified and quantified.

    • Main Results:

    • Chromosomal imbalances were detected in 12 out of 13 cases.
    • Common aberrations included loss of chromosome 9 (-9, 77%), gain of chromosome 1q (+1q, 38%), loss of chromosome 3 (-3, 31%), and loss of 22q (-22q, 23%).
    • WHO grade II cases showed fewer imbalances (1.4 per case) than WHO grade III cases (3.5 per case). Loss of chromosome 9 was prevalent in both grades (40% in grade II, 100% in grade III).
    • WHO grade III cases were characterized by +1q (63%), +13q (25%), -9 (100%), -3 (38%), and -22q (25%).

    Conclusions:

    • Clear cell ependymomas exhibit distinct chromosomal aberration patterns compared to other ependymoma variants.
    • Loss of chromosome 9 is a significant molecular hallmark of clear cell ependymomas.
    • The observed genetic differences between WHO grade II and III highlight distinct molecular pathways and potential prognostic implications.